ISSN: 2517-7370
Cancer is generally referred to as a disease that involves abnormal growth of cells that have the potential to spread in different parts of the body. The disease may be curable if detected in early stages. It is most prevalent disease ...
Explore the journal aims, scope and subject coverage before submission.
View editorial leadership and board information for this journal.
Browse current research articles and article updates from this journal.
Open Access publishing information is available for authors and readers.
Dr. Hamza Mujagic is former Visiting Scholar and Professor at Massachusetts General Hospital/ Harvard University/Harvard Cancer Center and former Clinical Review Board Member for Harvard University Cancer Center, Boston and former Consultant for Xanthus Pharmaceuticals, Cambridge, Massachusetts, USA. He graduated from the University of Zagreb Medical School in 1968 where he also received his basic clinical training and Board certification in Medicine. He obtained his Master's degree from the University of Zagreb in 1973 and his Ph.D. from the Universities of Essen, Germany, and the University of Zagreb in 1976. He received his specialty training in Nuclear Medicine in 1971-1972 and Clinical Oncology in 1972-1977 from Central Institute for tumors in Zagreb and Internal medicine from several clinical centers in Europe and from the University Medical Center in Sarajevo in 1980. He started his career in Translational Medicine as a Fellow of Scientific Fund of The Republic of Croatia combining his research at Institute Rudjer Boskovic/ University of Zagreb from 1969-1971 and clinical work at University Hospital “Merkur” in1972 and continued his career in translational medicine at Central Institute for tumors in Zagreb from 1971-1977. As a recipient of International Union Against Cancer (ICRETT) Award he worked in the National Cancer Institute/ National Institutes of Health of the USA in Bethesda from 1978-1979. He was then invited to join The National Cancer Institute and worked there from 1980-1984 and continued at the Memorial Sloan-Kettering Cancer Center, New York, from 1984-1985, at the Universities in Banjaluka and Tuzla and as a Visiting Scholar and Professor at Harvard University and Massachusetts General Hospital from 1997 and on, where he has spent most of his last 12 professional years. He is specialist in Internal Medicine/subspecialties Urologic Oncology and Cancer Pharmacology/ Immunology and is Professor of Medicine and Oncology. He published 106 research papers, was or is on the Editorial Boards of 5 international journals, reviewer for several scientific journals and is cited thus far 559 times. His areas of expertise are Urologic, lung, breast, GI and melanoma cancers, design and conduct of Clinical Trials, Cancer Chemotherapy and Immunotherapy, and Cancer drug analysis and writing. His latest working engagement: was as senior Consultant and Professor at Lanssjukhus Sundsvall/Umea University, Department of Oncology, Sundsvall, Sweden. Currently, he is in private practice.
Discover peer-reviewed open access journals across diverse disciplines.
